Do female sex hormones initiate breast cancer? A review of the evidence

References

• US National Institute of Environmental Health Science - Biennial Report of Carcinogens, De-cember 2002, 10th Edition. US Congress Reports
   Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350:1047–59
   PubMed Web of Science ®Google Scholar
• Schairer C, Lubin J, Troisis R, et al. Menopausal estrogen and estrogen/progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485–91
   PubMed Web of Science ®Google Scholar
• Ross RK, Paganini-Hill A, Wan PC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328–32
   PubMed Web of Science ®Google Scholar
• Million Women Collaborators. Breast cancer and hormone replacement in the Million Women Study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initia-tive Investigators. Risks and benefits of estrogen plus progestin in healthy postmeno-pausal women. J Am Med Assoc 2002;288:321–33
   Google Scholar
• Phillips KA, Glendon G, Knight J. Putting the risk of breast cancer in perspective. N Engl J Med 1999;340:141–4
   PubMed Web of Science ®Google Scholar
• Henderson IC. Risk factors for breast cancer development. Cancer 1993;Suppl 71:2127–40
   Google Scholar
• Kricker A, Jelf P. Risks of breast cancer by age: Cancer Series No. 6. Breast cancer in Australian women 1921–1994. Australian Institute of Health and Welfare National Health and Medical Research Council. Na-tional Breast Cancer Centre, Canberra, 1996:13
   Google Scholar
• Trichopoulos D, MacMahon B, Cole P. Meno-pause and breast cancer risk. J Natl Cancer Inst 1972;48:605–13
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. Australian Association of Cancer Registries and NHMRC National Breast Cancer Centre 1999: Breast Cancer in Australian Women 1982–1996, Canberra AIHW (Cancer Series)
   Google Scholar
• Kelsey JL, Gammon MD, John EM. Reproduc-tive factors and breast cancer. Epidemiol Rev 1993;15:36–47
   Google Scholar
• MacMahon B, Cole P, Lim M, et al. Age at first birth and breast cancer risk. Bull WHO 1970; 43:209–21
   PubMed Web of Science ®Google Scholar
• Layde PM, Webster LA, Baugham AL, et al. The independent association of parity, age at first full term pregnancy and duration of breast feeding with the risk of breast cancer. J Clin Epidemiol 1989;42:963–73
   PubMed Web of Science ®Google Scholar
• Romieu I, Berlin JA, Colditz G. Oral contra-ception and breast cancer: review and meta-analysis. Cancer 1990;66:2253–63
   Google Scholar
• Malone KE, Darling JR, Weiss MS. Oral contra-ception and breast cancer risk. Epidemiol Rev 1993;15:80–97
   Google Scholar
• Thomas DB. Oral contraceptives and breast cancer: review of the epidemiological literature. Contraception 1991;1:973–82
   Google Scholar
• UK National Case—Control Study Group. Oral contraceptive and breast cancer risk. Epidemiol Rev 1993;15:597–641
   Google Scholar
• Yeates D. Report: MRC/FPA Study of Contra-ception and Women's Health. Oxford University, Unit of Health Care Epidemiol-ogy, Dept of Public Health, Oxford, 2003:1–2
   Google Scholar
• Blankenstein MA, Syzmczak J, Daroszewski J, et al. Estrogen in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncogenic reasons. Gynecol Endocrinol 1992;6:13
   PubMed Web of Science ®Google Scholar
• Pasqualini JR, Chetrite G. Control of estrone sulfatase activity in human breast cancer cells: effect of tibolone and its metabolites. Gynecol Endocrinol 1996;11:69–75
   Google Scholar
• Bulun SE, Price TM, Aitken J, et al. A link between breast cancer and local estrogen bio-synthesis suggested by quantification of breast adipose tissue competitive polymerase chain reaction after reverse transcription. J Clin En-docrinol Metab 1993;77:1622–8
   PubMed Web of Science ®Google Scholar
• Rose C, Mouridsen HT. Endocrine management of advanced breast cancer. Horm Rev 1989; 32(Suppl 1):189–97
   PubMedGoogle Scholar
• Ingle JN, Ahman DL, Green SJ, et al. Rando-mised clinical trial of megestrol acetate versus tamoxifen in perimenopausal or castrated wo-men with advanced breast cancer. Am J Clin Oncol (CCT) 1982;5:155–6
   PubMed Web of Science ®Google Scholar
• Persson L, Yuen J, Bergkvist I, et al. Combined oestrogen/progestogen replacement therapy andbreastcancerrisk.Lancet1992;340:1044–6
   PubMed Web of Science ®Google Scholar
• Weiss LK, Burkman RT, Cushing-Huagen KL. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002;100: 1148–58
   Google Scholar
• Ng EH, Gao F, Ji CY, et al. Risk factors for breast carcinoma in Singaporean Chinese wo-men: the role of central obesity. Cancer 1997; 80:725–31
   PubMed Web of Science ®Google Scholar
• Moorman PG, Kuwabara H, Millikan RC, Newman B. Menopause hormones and breast cancer in a biracial population. Am J Pub Health 2000;90:966–71
   PubMed Web of Science ®Google Scholar
• Bush T, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a quali-tative review. Obstet Gynecol 2001;98:498–508
   Google Scholar
• Lando JF, Heck KE, Brett KM. Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prey Med 1999;17:176–80
   Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70
   PubMed Web of Science ®Google Scholar
• Creasman WT, Hoel D, DiSaia PJ. WHI: now that the dust has settled. Am J Obstet Gynecol 2003;189:621–6
   PubMed Web of Science ®Google Scholar
• Fedi P, Tronick SR, Aaronson SA. Growth factors. In Holland JF, Bast RC, Morton DL, Frei E, Kufe DW, Weichselbaum RR, eds. Cancer Medicine. Baltimore: Williams and Wilkins, 1997:41–4
   Google Scholar
• Hunter T. Oncoprotein networks. Cell 1997; 898:333–46
   Google Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323–30
   PubMed Web of Science ®Google Scholar
• Foley KP, Eisenman RN. Two MAD tails: what the recent knockouts of Mad 1 and M x 2 tell us about MYC/MAX/MAD networks. Biochem Biophys Acta 1999;1423:M37–47
   PubMed Web of Science ®Google Scholar
• Moses HL, Yang EY, Pietenpol JA. TGFfl stimulation and inhibition of cell cycle arrest. Nature 1994;371:257–61
   Google Scholar
• Hannan GJ, Beach B. P15 INK 48 is a potential effector of TGFfl induced cell cycle arrest. Nature 1994;371:257–61
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. Steroidal control of cell proliferation in the breast and breast cancer. In Wren B G, ed. Progress in the Management of the Menopause. Carnforth, UK: Parthenon, 1996:194–202
   Google Scholar
• Musgrove EA, Sutherland RL. Cell cycle control by steroid hormones. In Parker M G, ed. Seminars in Cancer Biology. London: Academic Press, 1994;5:381–98
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Hui R, Sweeney KJE, et al. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 1996;1:153–62
   PubMed Web of Science ®Google Scholar
• Groshong SD, Owen GI, Grimson B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of cyclin-dependent kinase inhibitors P21 and P27KIP 11. Mol Endocrinol 1991;11:1593–607
   Google Scholar
• Musgrove EA, Lee CSL, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression whilst increasing expression of transforming growth factor a, epidermal growth factor receptor, c-fos and c-myc genes. Mol Cell
   Google Scholar
• Ashkenazi A, Dixit VM. Apoptosis by death and decoy receptors. Curr Opin Cell Biol 1999;11:255–60
   PubMed Web of Science ®Google Scholar
• Giancotti FG, Ruoslahti E. Integrin signalling. Science 1999;285:1028–32
   PubMed Web of Science ®Google Scholar
• Hayflick L. Mortality and immortality at the cellular level: a review. Biochemistry 1997;62: 1180–90
   PubMed Web of Science ®Google Scholar
• Bryan TM, Cech TR.Telomerase and the main-tenance of chromosome ends. Curr Opin Cell Biol 1999;11:318
   PubMed Web of Science ®Google Scholar
• Bouck M, Stellmack V, Hsu SC. How tumours become angiogenic. Adv Cancer Res 1996:69: 135–74
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging
   Google Scholar
• Kim KJ, Li B, Winer J. Inhibition of vascular endothelial growth factor-induced angiogenesis
   Google Scholar
• Sporn MB. The war on cancer. Lancet 1996; 347:1377–81
   PubMed Web of Science ®Google Scholar
• Christofori G, Semb H. The role of the cell adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999; 24:73–6
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Lee CSL, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci 1994;91:8022–6
   PubMed Web of Science ®Google Scholar
• Sutherland RL, Watts CKW, Musgrove EA. Cell cycle control by steroid hormones in breast cancer: implications for endocrine resistance. Endocrine Related Cancer 1995;2:87–96
   Google Scholar
• Pasqualini JR, Chetrite G. Control of oestrone sulfatase activity in human breast cancer cells: effect of tibolone and its metabolites. Gynecol Endocrinol 1996;11:69–75
   Google Scholar
• Geisler J, King N, Dowsett M, et al. Influence of anastrazole (Arimidex), a selective non-steroidal aromatase inhibitor on in-vivo aromatisation and plasma oestrogen level in post menopausal women with breast cancer. Br J Cancer 1996; 74:1286–91
   PubMed Web of Science ®Google Scholar
• Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol 1999;106:1–21
   PubMedGoogle Scholar
• Graham JD, Clarke CL. Physiological action of progesterone in target tissue. Endocrine Rev 1997;18:502–18
   PubMed Web of Science ®Google Scholar
• Russo J, Russo IH. Role of hormones in human breast development: the menopausal breast. In Wren BG, ed. Progress in the Management of the Menopause. Proceedings of the 8th Interna-tional Congress on the Menopause. Carnforth, UK: Parthenon, 1996:184–93
   Google Scholar
• Hankinson S, Willett WC, Manson JE, et al. Plasma sex steroid levels and risk of breast cancer in post menopausal women. J Natl Cancer Inst 1998;90:1292–7
   PubMed Web of Science ®Google Scholar
• Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous oestro-gens and breast cancer in post menopausal women. J Natl Cancer Inst 1995;87:190–7
   PubMed Web of Science ®Google Scholar
• Plu-Bureau G, Le MG, Sitruk-Ware R, et al. Progestogen use and decreased risk of breast cancer in a cohort study of pre-menopausal women with benign breast disease. Br J Cancer 1995;70:270–7
   Google Scholar